Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by attila9on Jan 28, 2004 4:59pm

154 Views

Post# 6967897

RE: need clarification

Your absolutely correct.It must have been a he## of a contract as you can clearly see in the management discussion financials.The sales & profits sky rocketed after this deal.Oh well it's more than they have done in a long time so i guess one should be grateful for any progress these guys make.EOM!!!!

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload